Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment

Hypomethylating agents (HMAs) are widely used in patients with higher-risk MDS not eligible for stem cell transplantation. However, the general response rate by HMAs is lesser than 50% in MDS patients, while the relapse rate is high. Emerging evidence indicates that demethylating effects committed b...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Suxia Geng, Ruohao Xu, Xin Huang, Minming Li, Chengxin Deng, Peilong Lai, Yulian Wang, Ping Wu, Xiaomei Chen, Jianyu Weng, Xin Du
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Subjects:	Myelodysplastic syndromes (MDS) programmed death protein 1 (PD-1) programmed death-ligand 1 (PD-L1) programmed death-ligand 2 (PD-L2) hypomethylating agent (HMA)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.950134/full